MX2022000847A - Dosificacion para la prevencion o tratamiento de la enfermedad de injerto contra huesped (gvhd) con proteinas de fusion il-22 fc. - Google Patents

Dosificacion para la prevencion o tratamiento de la enfermedad de injerto contra huesped (gvhd) con proteinas de fusion il-22 fc.

Info

Publication number
MX2022000847A
MX2022000847A MX2022000847A MX2022000847A MX2022000847A MX 2022000847 A MX2022000847 A MX 2022000847A MX 2022000847 A MX2022000847 A MX 2022000847A MX 2022000847 A MX2022000847 A MX 2022000847A MX 2022000847 A MX2022000847 A MX 2022000847A
Authority
MX
Mexico
Prior art keywords
gvhd
host disease
versus host
graft versus
dosing
Prior art date
Application number
MX2022000847A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Kalo
Siddharth Sukumaran
Peter William Day
Yehong Wang
Timothy Then- Chioh Lu
Melicent Clare Peck
Chin Yat Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022000847A publication Critical patent/MX2022000847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022000847A 2019-07-26 2020-07-24 Dosificacion para la prevencion o tratamiento de la enfermedad de injerto contra huesped (gvhd) con proteinas de fusion il-22 fc. MX2022000847A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879306P 2019-07-26 2019-07-26
US202062976321P 2020-02-13 2020-02-13
PCT/US2020/043542 WO2021021647A1 (en) 2019-07-26 2020-07-24 Dosing for prevention or treatment of graft versus host disease (gvhd) with il-22 fc fusion proteins

Publications (1)

Publication Number Publication Date
MX2022000847A true MX2022000847A (es) 2022-02-10

Family

ID=72087164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000847A MX2022000847A (es) 2019-07-26 2020-07-24 Dosificacion para la prevencion o tratamiento de la enfermedad de injerto contra huesped (gvhd) con proteinas de fusion il-22 fc.

Country Status (11)

Country Link
US (2) US20210023176A1 (ko)
EP (1) EP4003400B1 (ko)
JP (1) JP2022542240A (ko)
KR (1) KR20220041146A (ko)
CN (1) CN114206373A (ko)
AU (1) AU2020320866A1 (ko)
CA (1) CA3143633A1 (ko)
IL (1) IL289900A (ko)
MX (1) MX2022000847A (ko)
TW (1) TW202118793A (ko)
WO (1) WO2021021647A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117542529B (zh) * 2024-01-10 2024-04-02 北京博富瑞基因诊断技术有限公司 Hla不相合异基因造血干细胞移植非复发死亡风险的预测方法、系统、设备、存储介质

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP2560683B2 (en) 2010-04-23 2022-07-20 F. Hoffmann-La Roche AG Production of heteromultimeric proteins
US8239366B2 (en) 2010-09-08 2012-08-07 Nuance Communications, Inc. Method and apparatus for processing spoken search queries
CR20150477A (es) * 2013-03-15 2015-10-26 Genentech Inc Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
ES2676023T3 (es) * 2013-03-15 2018-07-16 F. Hoffmann-La Roche Ag Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
US20160287670A1 (en) * 2013-11-07 2016-10-06 Memorial Sloan-Kettering Cancer Center Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
LT3743088T (lt) * 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
KR20200115546A (ko) * 2018-01-26 2020-10-07 제넨테크, 인크. IL-22 Fc 융합 단백질 및 사용 방법
AU2019226085A1 (en) * 2018-02-21 2020-09-17 Genentech, Inc. Dosing for treatment with IL-22 Fc fusion proteins

Also Published As

Publication number Publication date
KR20220041146A (ko) 2022-03-31
CN114206373A (zh) 2022-03-18
EP4003400A1 (en) 2022-06-01
EP4003400B1 (en) 2024-04-03
WO2021021647A1 (en) 2021-02-04
US20220144910A1 (en) 2022-05-12
EP4003400C0 (en) 2024-04-03
AU2020320866A1 (en) 2022-01-20
US20210023176A1 (en) 2021-01-28
JP2022542240A (ja) 2022-09-30
CA3143633A1 (en) 2021-02-04
TW202118793A (zh) 2021-05-16
IL289900A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2018002183A (es) Composiciones y metodos para tratamiento del dolor.
MY195443A (en) Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
MX2020008502A (es) Dosis para el tratamiento con proteinas de fusion il-22 fc.
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2020007628A (es) Composiciones y metodos de uso.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA202193038A1 (ru) Антитела против sema3a и их применения для лечения заболеваний глаз
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2022001626A (es) Composiciones biofarmaceuticas y procedimientos conexos.
MX2022000847A (es) Dosificacion para la prevencion o tratamiento de la enfermedad de injerto contra huesped (gvhd) con proteinas de fusion il-22 fc.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
EP4249503A3 (en) Vsig8-based chimeric proteins
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.